TrialCompass TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT06854653

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is comparing PTX-100 against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 6 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

PTX-100 (DRUG): Peptidomimetic inhibitor of GGTase 1

Drugs / treatments
PTX-100
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

NCT06854653

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is comparing PTX-100 against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 6 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

PTX-100 (DRUG): Peptidomimetic inhibitor of GGTase 1

Drugs / treatments: PTX-100

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, open-label

Enrollment target: 115 patients

Primary endpoint: To determine the efficacy of PTX-100 as determined by ORR.

Ages: 18 Years to —

Start date: 2025-03-28 | Est. completion: 2028-06

Locations

6 US sites · 15 total

California, Connecticut, Massachusetts, New York, Virginia

Contact

Upaly Bahadure | upaly@ptxtherapeutics.com | +61 3 9692 7222

Sponsor: Prescient Therapeutics, Ltd. (INDUSTRY)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06854653

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.